NEW YORK – With a pan-cancer local coverage determination for its Guardant360 test now finalized and US Food and Drug Administration approval anticipated in the first half of this year, Guardant Health has settled the major regulatory and reimbursement hurdles for its non-invasive advanced cancer genotyping and can now accelerate its efforts in cancer screening and early-stage adjuvant testing, and focus on new companion diagnostic associations for its flagship test.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.